thiazoles has been researched along with Leukemia, Myelogenous, Aggressive Phase in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abruzzo, L; Alattar, ML; Borthakur, G; Champlin, R; Cortes, JE; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Luthra, R; O'Brien, S; Ohanian, M; Pierce, S; Quintas-Cardama, A; Ravandi, F; Trinh, LX; Verstovsek, S | 1 |
| Dolan, M; Rabenau, KE; Ustun, C; Yohe, S | 1 |
| Augustin, M; Baumgartner, C; Bennett, KL; Colinge, J; Hantschel, O; Müller, A; Remsing Rix, LL; Rix, U; Stranzl, T; Superti-Furga, G; Till, JH; Valent, P | 1 |
| Borthakur, G; Cortes, J; Fava, C; Garcia-Manero, G; Jabbour, E; Jain, N; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Verstovsek, S | 1 |
| Bradley-Garelik, MB; Cortes, J; DiPersio, J; Dorlhiac-Llacer, P; Kantarjian, H; Khoroshko, N; Khoury, HJ; Kim, DW; Müller, MC; Pasquini, R; Radich, JP; Tallman, MS; Zhu, C | 1 |
| Abruzzese, E; Baccarani, M; Bhatia, R; Bosly, A; Cortes, J; Dünzinger, U; Facon, T; Fischer, T; Gallagher, NJ; Giles, FJ; Goldberg, S; Jagasia, M; Kam, GL; Kantarjian, HM; Kim, DW; Larson, RA; Mahon, FX; Marin, D; Mendrek, W; Mueller, MC; Rosti, G; Shou, Y | 1 |
| Barbany, G; Engdahl, I; Hermansson, M; Höglund, M; Lundán, T; Ohm, AC; Olsson-Strömberg, U; Porkka, K; Simonsson, B | 1 |
| Demarquet, M; Labussière-Wallet, H; Nicolas-Virelizier, E; Nicolini, FE | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J | 1 |
| Araki, E; Furukawa, N; Kawaguchi, T; Kikukawa, Y; Ono, K; Shimomura, T; Suzushima, H; Watanabe, Y | 1 |
| Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Muscaritoli, M; Stefanizzi, C | 1 |
2 review(s) available for thiazoles and Leukemia, Myelogenous, Aggressive Phase
| Article | Year |
|---|---|
[A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia].
Topics: Aniline Compounds; Antineoplastic Agents; Blast Crisis; Dasatinib; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2012 |
3 trial(s) available for thiazoles and Leukemia, Myelogenous, Aggressive Phase
| Article | Year |
|---|---|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure; Young Adult | 2009 |
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Genes, abl; Heart Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; International Agencies; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
6 other study(ies) available for thiazoles and Leukemia, Myelogenous, Aggressive Phase
| Article | Year |
|---|---|
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome.
Topics: Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Accelerated Phase; Philadelphia Chromosome; Pyrimidines; Thiazoles | 2014 |
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Topics: Aniline Compounds; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dasatinib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid, Accelerated Phase; Leukocytes, Mononuclear; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Nerve Tissue Proteins; Nitriles; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinolines; Signal Transduction; src-Family Kinases; Substrate Specificity; Thiazoles | 2009 |
Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Topics: Adolescent; Adult; Aged; Clone Cells; Dasatinib; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Neoplasm; Thiazoles; Young Adult | 2010 |
Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hyperglycemia; Hypoglycemic Agents; Imatinib Mesylate; Insulin; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Complications; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2008 |